Solriamfetol reduces sleepiness in patients with OSA, narcolepsy

24 Jan 2023
Solriamfetol reduces sleepiness in patients with OSA, narcolepsy

A recent study has shown the efficacy of solriamfetol as an alternative treatment for managing excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnoea (OSA).

The research team accessed the database of PubMed (1966 to January 2011) using the terms solriamfetol, JZP-110, ADX-N05, and Sunosi. They identified and reviewed human studies published in peer-reviewed medical journals in English language.

Two phase II trials and four phase III trials (TONES 2, 3, 4, and 5) reported the efficacy and safety of solriamfetol. Specifically, treatment with solriamfetol 150 and 300 mg resulted in statistically significant improvements in the maintenance of wakefulness test compared with placebo in individuals with narcolepsy (7.65- to 10.14-minute difference vs placebo).

Among individuals with OSA, statistically significant improvements in maintenance of wakefulness test were likewise seen in those treated with solriamfetol 75, 150, or 300 mg compared with placebo (4.5- to 12.8-min difference from placebo).

The phase III trials also reported statistically significant reductions in Epworth Sleepiness Scale scores in individuals with narcolepsy or OSA receiving solriamfetol (range, ‒4.7 to ‒1.9 difference from placebo). Adverse events commonly reported in these trials included headache, nausea, decreased appetite, anxiety, dry mouth, and diarrhoea.

In addition, “[s]olriamfetol appears to have a reduced risk for drug interactions and fewer adverse effects compared to other agents available for management of EDS in patients with narcolepsy and OSA,” the researchers said.

Editor's Recommendations